The Context
No major Asian drugmaker has committed capital at this scale to Latin American vaccine manufacturing. Colombia’s push to localize vaccine supply follows pandemic-era import disruptions that left the region dangerously exposed. SK’s entry reshapes the regional pharmaceutical landscape.
The Takeaway
Watch for parallel plays in Mexico and Brazil — governments with post-pandemic vaccine mandates will favor local manufacturers over import-dependent models. Boards at U.S. pharma distributors serving Latam should reassess contract exposure as local capacity scales.
Source: Fiercepharma